Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Authors
Keywords
Diabetes, Lipids, Lipoproteins, Dyslipidemia, Treatments, Cardiovascular disease
Journal
Current Cardiology Reports
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-01-28
DOI
10.1007/s11886-017-0818-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone SignalingHighlights
- (2016) Jing Liu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Managing dyslipidaemia in type 2 diabetes mellitus
- (2016) Auryan Szalat et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus
- (2016) Cecilia C. Low Wang et al. CIRCULATION
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
- (2016) Changting Xiao et al. DIABETES
- Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
- (2016) John P.H. Wilding et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures
- (2016) Joseph P. Drozda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial
- (2015) Stephen J. Nicholls et al. AMERICAN HEART JOURNAL
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
- (2015) Norm Rosenthal et al. Annals of the New York Academy of Sciences
- Dietary fatty acids, dietary patterns, and lipoprotein metabolism
- (2015) Benoît Lamarche et al. CURRENT OPINION IN LIPIDOLOGY
- Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
- (2015) Changting Xiao et al. DIABETES
- Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
- (2015) Stephan Matthaei et al. DIABETES CARE
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role for Combination Therapy in Diabetic Dyslipidemia
- (2015) Haider J. Warraich et al. Current Cardiology Reports
- Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study
- (2014) Wenjie Ma et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus
- (2014) Maria J. Gutierrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Prevalence and Incidence Trends for Diagnosed Diabetes Among Adults Aged 20 to 79 Years, United States, 1980-2012
- (2014) Linda S. Geiss et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
- (2014) Kira B. Harris et al. Therapeutic Advances in Endocrinology and Metabolism
- The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
- (2014) Eun Yeong Choe et al. Diabetes & Metabolism Journal
- Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids
- (2013) Marius R. Robciuc et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
- (2013) Hanford Yau et al. Current Diabetes Reports
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol
- (2012) Vineeta Sharma et al. CURRENT OPINION IN LIPIDOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Is it time to revise the HDL cholesterol hypothesis?
- (2012) Daniel J Rader et al. NATURE MEDICINE
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Electronegative low-density lipoprotein: Origin and impact on health and disease
- (2011) Ana Paula Queiroz Mello et al. ATHEROSCLEROSIS
- Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes: ACCORD trial
- (2011) R. T. Anderson et al. DIABETES CARE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
- (2008) Martin Adiels et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Intestinal lipoprotein overproduction in insulin-resistant states
- (2008) Khosrow Adeli et al. CURRENT OPINION IN LIPIDOLOGY
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?
- (2008) Sheila A Doggrell EXPERT OPINION ON PHARMACOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now